2019 Competition Prescription 
World of DTC Marketing
AUGUST 19, 2022
It’s no wonder that voters consistently rank bringing down prescription drug prices and other measures to reduce the cost of care as among Congress’ top priorities. Congress rightly chose to negioate drug prices for Medicare, but prescription drugs are only 10-12% of every healthcare dollar we spend.
World of DTC Marketing
MARCH 1, 2022
Hospitals, physicians, and clinical care made up more than half of the total healthcare spending in 2019. The lack of choice limits competition, which can drive prices higher. According to KFF, “ the cost of health care often prevents people from getting needed care or filling prescriptions. Half of U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
MARCH 17, 2021
Pharma has gone to court again and again to delay generic competition of biologic drugs. One company AbbVie has used the courts to stop competition of its top drug Humira. For 2020, AbbVie’s handing its longtime CEO $24 million in total pay, up from 2019’s $21.6 In fact, Richard Gonzalez, C.E.O.
World of DTC Marketing
OCTOBER 5, 2021
Seventy-nine percent of Americans think the price of prescription drugs is “unreasonable,” according to a 2019 Kaiser Family Foundation poll , and about 9 in 10 say they support the idea of the government negotiating prices. Via Axios “The 10 highest-selling drugs in the U.S.
World of DTC Marketing
JANUARY 31, 2021
The cost of bringing a drug to market decreased from $2,168 million in 2018 to $1,981 in 2019. Pharma is NOT blameless, but like I have said in the past, even if all prescription drugs were free, healthcare costs would still be unsustainable in this country. In pharma R&D returns have declined to 1.8 percent from 2018.
pharmaphorum
NOVEMBER 16, 2022
Novartis completed the spin-out of Alcon in 2019, separating products like contact lenses and over-the-counter eyedrops from its prescription eye medicines, headed by age-related macular degeneration (AMD) blockbuster Lucentis (ranibizumab), which is partnered with Roche. billion in the first nine months of this year.
Pharmaceutical Technology
JANUARY 30, 2023
For 2019–23, this was capped at 2% per year. During 2019–21, when sales being close to predicted levels resulted in single-digit payback rates, the scheme was relatively popular with the pharma sector.
Expert insights. Personalized for you.
204 
Let's personalize your content